Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Keynote Address
  • Published:

Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia

Leukemia volume 18, pages 1927–1930 (2004)Cite this article

The objectives of this article are firstly to review the function and clinical relevance of p-glycoprotein (pgp) in AML and secondly to review the current status of trials using pgp modulation and discuss why these have shown apparently conflicting results. Finally, we wish to discuss alternative strategies for overcoming drug resistance in AML.

P-glycoprotein (pgp), the product of the MDR1 gene, is a 170 kDa ATP-binding cassette (ABC) membrane transporter. (The gene is now also known as ABCB1 in the ABC transporter nomenclature.)

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Leith C . Multidrug resistance in leukemia. Curr Opin Hematol 1998; 5: 287–291.

    Article  CAS  PubMed  Google Scholar 

  2. Pallis M, Turzanski J, Higashi Y, Russell N . P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43: 1221–1228.

    Article  CAS  PubMed  Google Scholar 

  3. Del Poeta G, Venditti A, Stasi R, Aronica G, Cox MC, Buccisano F et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 1999; 23: 451–465.

    Article  CAS  PubMed  Google Scholar 

  4. Pallis M, Russell N . P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000; 95: 2897–2904.

    CAS  PubMed  Google Scholar 

  5. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ . A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000; 38: 1–11.

    Article  CAS  PubMed  Google Scholar 

  6. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD . Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997; 36: 11169–11178.

    Article  CAS  PubMed  Google Scholar 

  7. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW . The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998; 95: 7024–7029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Johnstone R, Cretney E, Smyth M . P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075–1085.

    CAS  PubMed  Google Scholar 

  9. Gollapudi S, Gupta S . Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001; 21: 420–430.

    Article  CAS  Google Scholar 

  10. Lavie Y, Liscovitch M . Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000; 17: 253–259.

    Article  CAS  PubMed  Google Scholar 

  11. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP . Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the p-glycoprotein blocker PSC833. FASEB J 1998; 12: 101–109.

    Article  CAS  PubMed  Google Scholar 

  12. Lala P, Ito S, Lingwood CA . Retroviral transfection of Madin–Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis. J Biol Chem 2000; 275: 6246–6251.

    Article  CAS  PubMed  Google Scholar 

  13. Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002; 16: 1111–1113.

    Article  CAS  PubMed  Google Scholar 

  14. Garrigues A, Escargueil AE, Orlowski S . The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 2002; 99: 10347–10352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC . Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996; 271: 19530–19536.

    Article  CAS  PubMed  Google Scholar 

  16. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y et al. Possible role of ceramide as an indicator of chemoresistance: decrease of ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukaemia. Clin Cancer Res 2003; 8: 415–423.

    Google Scholar 

  17. Shabbits JA, Mayer LD . P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002; 1: 205–213.

    CAS  PubMed  Google Scholar 

  18. Turzanski J, Grundy M, Russell N, Pallis M . P-glycoprotein is implicated in the inhibition of ceramide induced apoptosis in acute myeloid leukaemia by more than one mechanism: evidence for the involvement of the glucosylceramide synthase pathway in TF1 but not in KG1a cells. Exp Hematol 2004, accepted for publication.

  19. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301–2307.

    Article  CAS  PubMed  Google Scholar 

  20. Wang CY, Mayo MW, Baldwin Jr AS . TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784–787.

    Article  CAS  PubMed  Google Scholar 

  21. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS . NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923–5929.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220–16225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A et al. Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood 2003; 101: 1543–1550.

    Article  PubMed  Google Scholar 

  24. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996; 88: 1198–1205.

    CAS  PubMed  Google Scholar 

  25. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015–1024.

    Article  CAS  PubMed  Google Scholar 

  26. Solary E, Drenou B, Campos L, De Cremoux P, Mugneret F, Moreau P et al. Quinine as a multidrug resistance inhibitor: a phase III multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003; 102: 1202–1210.

    Article  CAS  PubMed  Google Scholar 

  27. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212–3220.

    Article  CAS  PubMed  Google Scholar 

  28. Liu Yin JA, Wheatley K, Rees JK, Burnett AK . Comparison of ‘sequential’ vs ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113: 713–726.

    Article  CAS  PubMed  Google Scholar 

  29. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224–1232.

    CAS  PubMed  Google Scholar 

  30. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004; 22: 1078–1086.

    Article  CAS  PubMed  Google Scholar 

  31. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997; 272: 1682–1687.

    Article  CAS  PubMed  Google Scholar 

  32. Goulding CW, Giuliano AE, Cabot MC . SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 2000; 149: 143–151.

    Article  CAS  PubMed  Google Scholar 

  33. Lin X, Sikkink RA, Rusnak F, Barber DL . Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J Biol Chem 1999; 274: 36125–36131.

    Article  CAS  PubMed  Google Scholar 

  34. Pallis M, Turzanski J, Harrison G, Wheatley K, Langabeer S, Burnett AK et al. Use of standardised flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol 1999; 104: 307–312.

    Article  CAS  PubMed  Google Scholar 

  35. Pallis M, Turzanski J, Langabeer S, Russell N . Reproducible flow cytometric methodology for measuring multidrug resistance in leaukaemic blasts. In: Kaspers G, Pieters R, Veerman A (eds). Drug Resistance in leukaemia and Lymphoma III, Advances in Experimental Medicine and Biology, Vol 457. New York: Kluwer Academic, 1999. pp 77–88.

    Google Scholar 

  36. Pallis M, Das-Gupta E . The flow cytometric measurement of functional and phenotypic p-glycoprotein. In: Blumenthal DR (ed). Chemosensitivity: Methods and Protocols. Totowa, NJ: Humana Press, 2004.

    Google Scholar 

  37. Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D et al. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 1999; 13: 786–791.

    Article  CAS  PubMed  Google Scholar 

  38. Higashi Y, Turzanski J, Pallis M, Russell NH . Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. Br J Haematol 2000; 111: 565–569.

    Article  CAS  PubMed  Google Scholar 

  39. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988–994.

    Article  CAS  PubMed  Google Scholar 

  40. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL . A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24: 533–537.

    Article  CAS  PubMed  Google Scholar 

  41. Newman A, Clutterbuck RD, Powles RL, Millar JL . Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. Leukemia 1994; 8: 274–280.

    CAS  PubMed  Google Scholar 

  42. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE . Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628–3634.

    Article  CAS  PubMed  Google Scholar 

  43. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000; 14: 1444–1450.

    Article  CAS  PubMed  Google Scholar 

  44. Lavie Y, Fiucci G, Liscovitch M . Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273: 32380–32383.

    Article  CAS  PubMed  Google Scholar 

  45. Hinrichs JW, Klappe K, Hummel I, Kok JW . ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells. J Biol Chem 2004; 279: 5734–5738.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, School of Molecular Medical Sciences, University of Nottingham and Nottingham City Hospital, UK

    M Pallis & N Russell

Authors
  1. M Pallis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Russell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pallis, M., Russell, N. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia. Leukemia 18, 1927–1930 (2004). https://doi.org/10.1038/sj.leu.2403511

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403511

This article is cited by

Search

Advanced search

Quick links